Blue Earth Diagnostics, a Bracco company developing PET radiopharmaceuticals, has appointed Marco Campione as its new chief executive officer.

Campione, who brings over 25 years of global experience in diagnostic imaging agents and radiopharmaceuticals, will report to Bracco Imaging CEO Fulvio Renoldi Bracco. He will also join the Blue Earth Diagnostics Ltd. board and serve as vice chair of the Blue Earth Diagnostics Inc. board.

David Gauden, co-founder and former CEO of Blue Earth Diagnostics, will transition to a full-time CEO role at Blue Earth Therapeutics, another Bracco subsidiary. This strategic move aims to enhance growth and leadership across both entities.

“We are thrilled to welcome Marco Campione to our team,” said Renoldi Bracco. “His extensive experience and strategic vision will be invaluable as we expand our global leadership in the diagnostic radiopharmaceutical industry. I also want to thank David Gauden for his significant contributions and wish him success in his new role.”

Campione previously served as executive director and global head of contrast media at GE HealthCare, where he also held roles as general manager of pharmaceutical diagnostics North America and president of GE HealthCare Inc.

Founded in 2014, Blue Earth Diagnostics, a subsidiary of Bracco Imaging, specializes in molecular imaging with a focus on PET radiopharmaceuticals for prostate cancer and neuro-oncology. Bracco Imaging, headquartered in Milan, Italy, is a global leader in diagnostic imaging modalities, including X-ray, MR, contrast enhanced ultrasound, and nuclear medicine.

Molecular Imaging Homepage